Clinical Trial

Tumour Characterisation to Guide Experimental Targeted Therapy - National

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 7, 2024 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary aim of TARGET National is to establish a national framework to offer molecular profiling of circulating tumour DNA and/or tumour tissue (optional) to patients with advanced solid cancers referred to any of the Experimental Cancer Medicine Centres (ECMCs) across the UK, in order to help decision making for allocation to molecularly targeted experimental cancer treatments. Patients will be allocated treatment using a national Molecular Tumour Board to find the most suited therapies based on their molecular profiling results. This study aims to recruit up to 6,000 patients with advanced solid tumours across 5 years and proposes to collect blood samples, archival tumour tissue and fresh tissue (optional) The data may also be used for future development of predictive cancer biological markers, the design of clinical trials involving new or existing drugs, discovery of new genetic targets and exploring how resistance to specific anticancer agents arises in patients to help improve future cancer treatment management.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-01-22; most recent amendment 2024-02-06.
Status change: Not Yet Recruiting → Recruiting 2021-08-09
Trial Details
NCT Number NCT04723316
Lead Sponsor The Christie NHS Foundation Trust
Conditions Cancer
Enrollment 6,000 participants
Start Date 2021-06-30
Primary Completion 2026-01-30 (estimated)
Study Completion 2028-01-30 (estimated)
Updated on ClinicalTrials.gov 2024-02-07